• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Silence Therapeutics Plc ADR (NQ: SLN )

17.99 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 6, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Silence Therapeutics Plc ADR

< Previous 1 2 3 4 Next >
Silence Therapeutics Appoints Dr. Steven Romano as Incoming Chief Medical Officer and Head of Research and Development
March 28, 2023
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics to Buyback siRNA Complement Assets
March 28, 2023
From Silence Therapeutics plc
Via Business Wire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
March 15, 2023
Via Benzinga
Silence Therapeutics' Thalassemia Hopeful Shows Favorable Safety Profile In Early Stage Study
September 29, 2022
Via Benzinga
Earnings Scheduled For March 15, 2023
March 15, 2023
Companies Reporting Before The Bell • Sportradar Gr (NASDAQ:SRAD) is estimated to report quarterly earnings at $0.04 per share on revenue of $208.09 million. 
Via Benzinga
Silence Therapeutics Reports Fourth Quarter and Full Year 2022 Results
March 15, 2023
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics to Report Fourth Quarter and Full Year 2022 Results on March 15, 2023
March 02, 2023
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics to Present at SVB Securities Global Biopharma Conference
February 08, 2023
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics Appoints J.P. Gabriel as Chief Technical Operations Officer
February 06, 2023
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics Provides SLN360 and SLN124 Clinical Program Updates
January 12, 2023
From Silence Therapeutics
Via Business Wire
Silence Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 03, 2023
From Silence Therapeutics
Via Business Wire
Why Coupa Software Shares Jumped Around 29%; Here Are 72 Biggest Movers From Wednesday
November 25, 2022
Gainers Kalera Public Limited Company (NASDAQ: KAL) jumped 76.9% to close at $0.1610 on Wednesday after gaining 9% on Tuesday. Kalera recently posted a Q3 loss of $0.05 per share. 
Via Benzinga
Silence Therapeutics Reports Third Quarter 2022 Results
November 10, 2022
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics to Present at Jefferies London Healthcare Conference
November 09, 2022
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics Presents New Analysis from SLN360 Phase 1 Single Dose Study in High Lipoprotein(a) at the American Heart Association (AHA) 2022 Annual Meeting
November 05, 2022
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics Announces Preliminary Single Dose Results from SLN124 Phase 1 Study in Patients with Thalassemia
September 29, 2022
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics to Participate in Fireside Chat at Chardan Genetic Medicines Conference
September 27, 2022
From Silence Therapeutics plc
Via Business Wire
Important Biotech Catalysts For September 8, 2022 - End Of The Day Summary
September 08, 2022
Via Benzinga
Silence Therapeutics Gets FDA Fast Track Status For Blood Cancer Candidate
September 08, 2022
Silence Therapeutics  (NASDAQ: SLN) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to its lead candidate SLN124 for the treatment of polycythemia vera... 
Via Benzinga
Silence Therapeutics to Participate in September Investment Conferences
September 08, 2022
From Silence Therapeutics plc
Via Business Wire
Silence Therapeutics Announces FDA Fast Track Designation for SLN124, a Novel Investigational siRNA Therapy for the Treatment of Polycythemia Vera
September 08, 2022
From Silence Therapeutics plc
Via Business Wire
Workday, Electronic Arts, Ulta Beauty And Some Other Big Stocks Moving Higher On Friday
August 26, 2022
  Micro Focus International plc (NYSE: MFGP) shares jumped 95.4% to $6.11 after the company reached an agreement with OpenText to be acquired for $6 billion. 
Via Benzinga
Silence Therapeutics Announces Pricing of Underwritten Offering
August 11, 2022
From Silence Therapeutics plc
Via Business Wire
This Biotechnology Stock Tumbled 37%; Here Are 70 Biggest Movers From Yesterday
August 19, 2022
Gainers Bright Minds Biosciences Inc. (NASDAQ: DRUG) shares climbed 135.9% to close at $2.17 on Thursday. 
Via Benzinga
Silence Therapeutics to Present at Jefferies Healthcare Conference
June 02, 2022
From Silence Therapeutics plc
Via Business Wire
Why Plus Therapeutics Is Trading Higher By Over 50%, Here Are 50 Stocks Moving In Thursday's Mid-Day Session
August 18, 2022
Gainers Bright Minds Biosciences Inc. (NASDAQ: DRUG) shares jumped 297% to $3.66. 
Via Benzinga
Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright Global Investment Conference
May 18, 2022
From Silence Therapeutics plc
Via Business Wire
76 Biggest Movers From Yesterday: Ocean Bio-Chem, Athira Pharma And More
June 23, 2022
Gainers Ocean Bio-Chem, Inc. (NASDAQ: OBCI) shares climbed 117.2% to close at $12.86 on Wednesday after the company announced it will be acquired by OneWater Marine for $13.08 per share in cash. 
Via Benzinga
Silence Therapeutics Reports First Quarter 2022 Results
May 16, 2022
From Silence Therapeutics plc
Via Business Wire
88 Biggest Movers From Yesterday
May 26, 2022
Gainers The Very Good Food Company Inc. (NASDAQ: VGFC) shares jumped 118.2% to close at $0.2950 on Wednesday as the company announced it increased retail distribution across Canada with Loblaw... 
Via Benzinga
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap